Rubish. They are continuing there trials and at this time have no new results, they will soon have more results. So I say TOTAL RUBISH to your reply Hail. They have learned from there mistake of saying possible partner talk. They should of never IMO mentioned anything before they had solid information of a partner. I do believe that they are in talks with partners but are bidding there time, they know the product they have and I feel its only time till we get great news. Again all IMO ONLY. You have your opinion, I have mine.
During a panel session at the meeting, it was noted that ganetespib and crizotinib activity in ALK+ NSCLC are likely to be complementary, rather than competitive, due to their distinct mechanisms of action. (((( Crizotinib, like other ALK inhibitors, inhibits the function of ALK by binding to the ALK protein itself; ))))
(((( ganetespib blocks the activation of ALK by targeting its dependence on the Hsp90 chaperone. )))) Ganetespib specifically, and Hsp90 inhibition generally, have been shown to be active in numerous models of ALK+ NSCLC for which the cancer cells have mutated and become resistant to treatment with crizotinib. At the panel session,
(((( it was announced that an investigator-sponsored trial evaluating the combination of ganetespib and crizotinib in ALK+ NSCLC patients is expected to initiate shortly. ))))